DaVita's Q2 Beat Doesn't Fix the Real Problem-But the Stock Still Looks Cheap

DaVita beat on Q2, but the rally had already done much of the repricing

DaVita's second quarter looked positive, but a 109.12% year-to-date gain suggests investors had already priced in much of the optimism before results arrived. Even before earnings, the stock was trading above some intrinsic-value estimates, with one model pegging fair value at $270 while shares hovered around $239.46. In that context, the quarter was less about uncovering hidden value than testing whether the improved narrative still held.

DaVita delivered diluted EPS of $4.02 and $256 million in free cash flow. That keeps the core bull case alive: the company is still producing earnings and cash from an existing network, not just a better story.

Scale and Berkshire ownership keep the bull case alive

Bulls can lean on scale and sponsorship. DaVita is the largest provider of dialysis services in the United States, and Berkshire Hathaway owns about 45% of the company. That large, long-term stake helps explain why the stock has had a steady base of support through the uncertainty.

The bear case is more about near-term pressure than survival. About two-thirds of U.S. sales come from Medicare, while profits are more heavily influenced by the smaller share of patients covered by commercial insurers. After this move, DaVita looks less like a hidden bargain and more like a proof trade: investors want continued execution, not just a clean quarter.

The valuation case rests on operating durability, not the headline beat

The undervaluation argument now depends less on one quarter and more on whether DaVita can keep turning its patient base into cash.

Why the asset base still matters

DaVita still serves approximately 296,300 patients across 3,262 outpatient dialysis centers. That scale matters because it supports a recurring revenue base tied to a slow-moving, highly regulated care model. For valuation, that is different from a cyclical business trying to regain lost demand.

The quarter also reinforced management's ability to convert that base into capital returns. In the first quarter, DaVita produced $3.416 billion in revenue, $482 million in operating income, and repurchased 3.0 million shares at an average price paid of $133.70 per share. In Q2, it generated $256 million in free cash flow and repurchased 2.2 million shares at an average price paid of $154.95 per share.

That is the real support for the bullish case now: not explosive growth, but margin durability and steady buybacks at prices well above where much of the recent base was built.

What has to hold for the stock to stay attractive

This is no longer an early-setup story. After the rally, the question is whether management can maintain the operating performance investors have already rewarded.

Watch two things:

• Cash generation: Free cash flow and share repurchases need to remain meaningful.
• Reimbursement pressure: Payer mix and Medicare exposure still cap how high the multiple can stretch.

If those elements hold, the stock can still justify further rerating on execution alone. If the operating math weakens, the undervaluation argument gets much harder to defend.

The analyst targets show how divided the market still is

With a 57.55% three-month gain, the debate is no longer about survival. It is about whether DaVita still has room to rise after such a fast repricing.

TD Cowen and UBS highlight the range of opinion

The latest consensus makes that clear. TD Cowen moved to a Buy with a $220 target, while UBS remains at a Buy with a $270 target. That spread captures the market's split view: bulls still see earnings power above the current price, while bears think expectations have risen enough that good is no longer enough.

What would confirm, and what would break, the case

Confirmation would look like another quarter in which DaVita defends the same engine investors already paid for: stable cash generation, continued buybacks, and no material deterioration in the operating model.

The setup weakens if cash returns slow or if reimbursement pressure starts to erode the margins that have supported the recovery story. The recent financing move shows the balance sheet is being managed, not that a new growth engine has appeared.

DaVita may still be undervalued, but after the move the stock now looks more like a confirmation trade than an obvious bargain.